Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer.
Subramanian
Prem S
PS
Wilmer Eye Institute, Baltimore, MD 21287, USA. psubram1@jhmi.edu
Kerrison
John B
JB
Calvert
Preston C
PC
Miller
Neil R
NR
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016727:Orbital Pseudotumor / Q000139:chemically induced* / Q000188:drug therapy; D000077268:Pamidronate; D011241:Prednisone / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000473:pathology*
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D004164:Diphosphonates; D000077268:Pamidronate; D011241:Prednisone